Blood
Herausgeber
Amer Soc Hematology
International Standard Serial Number (ISSN )
0006-4971
ISSN gedruckt
0006-4971
http://www.bibliothek.uni-regensburg.de/ezeit/?1468538-
2024
A lineage-speci fi c STAT5BN642H mouse model to study NK-cell leukemia
2024 Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.
2024 Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
2024 Tumor necrosis factor α promotes clonal dominance of KIT D816V+cells in mastocytosis: role of survivin and impact on prognosis
2024 Chromatin-Based Cellular Dependency of HOXA9/MEIS1-Driven Acute Myeloid Leukemia.
2024 Impact of Mono- and Bi-Allelic TP53 Aberrations on Transformation of Human HSPCs
2024 Ly6C+ Inflammatory Monocytes Create a Leukemia-Initiating Niche
2023 DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
2023 Duodenal macrophages control dietary iron absorption via local degradation of transferrin
2023 EVI1 drives leukemogenesis through aberrant ERG activation
2023 SBNO2 is a critical mediator of STAT3-driven hematological malignancies
2023 Targeting iron import to treat ANKL.
2023 Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib.
2022 Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress
2022 STAT1 and MHCII: guardians of stressed HSCs.
2022 DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage
2021 A STAT5B-CD9 axis determines self-renewal in and leukemic stem cells
2021 Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter
2021 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
2021 Mammalian VPS45 orchestrates trafficking through the endosomal system.
2021 Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity.
2020 CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
2020 IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
2020 Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling
2019 CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
2019 Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells
2019 BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact.
2019 CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis.
2019 Imatinib plus /- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR.
2019 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML).
2019 The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies.
2018 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
2018 Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
2018 BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML.
2017 CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
2017 First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
2017 Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients During Nilotinib Therapy.
2017 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies.
2016 Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
2016 Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml.
2016 Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib
2015 CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
2015 Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
2015 Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
2015 High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation.
2015 Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells.
2014 A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.
2014 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
2014 Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
2014 Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation.
2014 Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.
2014 Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome plus CML.
2014 Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia.
2013 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.
2012 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
2012 A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.
2012 Disruption of Mitochondrial Phosphatase Ptpmt1 Induces Bioenergetic Stress and Differentiation Block in Hematopoietic Stem Cells.
2012 Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats.
2012 TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia.
2011 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.
2011 High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
2011 Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.
2011 KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
2011 The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.
2011 c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5" region of Cdk6.
2011 5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells.
2011 Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a.
2011 New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas.
2011 Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML.
2011 Ponatinib Exerts Growth-Inhibitory Effects on Neoplstic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis.
2011 The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34(+)/CD38(-)/Lin(-) Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1 alpha.
2011 The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release.
2010 Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.
2010 STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
2010 Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.
2010 Bcr Abl Directly Activates Stat5 Independent of Jak2.
2010 The Aurora Kinase Inhibitor R763/AS703569 Exerts Major Growth Inhibitory and Apoptosis Inducing Effects on Neoplastic Mast Cells.
2009 Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
2008 Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
2008 Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
2008 Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.
2008 Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.
2008 Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
2008 Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax (R)) on Growth and Viability of Canine and Human Neoplastic Mast Cells.
2007 Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.
2007 Nonredundant roles for Stat5a/b in directly regulating Foxp3.
2007 The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
2006 Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.
2006 Interferons limit inflammatory responses by induction of tristetraprolin.
2005 CD molecules 2005: human cell differentiation molecules.
2005 Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
2004 Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.
2003 Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.
2003 JunB inhibits proliferation and transformation in B-lymphoid cells.
2002 Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.
2001 Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors.
2000 Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.
-
Gotthardt-Pötsch, Dagmar
2022 -
Kollmann, Karoline
2021 -
Grebien, Florian
2019 -
Hadzijusufovic, Emir
2016 -
Kenner, Lukas
2014 -
Klampfl, Thorsten
2014 -
Jensen-Jarolim, Erika
2012
-
2024
A lineage-speci fi c STAT5BN642H mouse model to study NK-cell leukemia
2024 Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.
2024 Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
2024 Tumor necrosis factor α promotes clonal dominance of KIT D816V+cells in mastocytosis: role of survivin and impact on prognosis
2024 Chromatin-Based Cellular Dependency of HOXA9/MEIS1-Driven Acute Myeloid Leukemia.
2024 Impact of Mono- and Bi-Allelic TP53 Aberrations on Transformation of Human HSPCs
2024 Ly6C+ Inflammatory Monocytes Create a Leukemia-Initiating Niche
2023 DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
2023 Duodenal macrophages control dietary iron absorption via local degradation of transferrin
2023 EVI1 drives leukemogenesis through aberrant ERG activation
2023 SBNO2 is a critical mediator of STAT3-driven hematological malignancies
2023 Targeting iron import to treat ANKL.
2023 Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib.
2022 Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress
2022 STAT1 and MHCII: guardians of stressed HSCs.
2022 DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage
2021 A STAT5B-CD9 axis determines self-renewal in and leukemic stem cells
2021 Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter
2021 Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
2021 Mammalian VPS45 orchestrates trafficking through the endosomal system.
2021 Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity.
2020 CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
2020 IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
2020 Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling
2019 CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks
2019 Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells
2019 BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact.
2019 CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis.
2019 Imatinib plus /- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR.
2019 Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML).
2019 The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies.
2018 Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
2018 Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
2018 BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML.
2017 CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
2017 First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
2017 Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients During Nilotinib Therapy.
2017 Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies.
2016 Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
2016 Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml.
2016 Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib
2015 CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
2015 Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
2015 Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
2015 High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation.
2015 Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells.
2014 A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.
2014 Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
2014 Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
2014 Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation.
2014 Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance.
2014 Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome plus CML.
2014 Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia.
2013 JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.
2012 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
2012 A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.
2012 Disruption of Mitochondrial Phosphatase Ptpmt1 Induces Bioenergetic Stress and Differentiation Block in Hematopoietic Stem Cells.
2012 Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats.
2012 TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia.
2011 A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.
2011 High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
2011 Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.
2011 KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
2011 The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.
2011 c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5" region of Cdk6.
2011 5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells.
2011 Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a.
2011 New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas.
2011 Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML.
2011 Ponatinib Exerts Growth-Inhibitory Effects on Neoplstic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis.
2011 The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34(+)/CD38(-)/Lin(-) Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1 alpha.
2011 The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release.
2010 Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.
2010 STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
2010 Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.
2010 Bcr Abl Directly Activates Stat5 Independent of Jak2.
2010 The Aurora Kinase Inhibitor R763/AS703569 Exerts Major Growth Inhibitory and Apoptosis Inducing Effects on Neoplastic Mast Cells.
2009 Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
2008 Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.
2008 Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
2008 Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.
2008 Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1.
2008 Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
2008 Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax (R)) on Growth and Viability of Canine and Human Neoplastic Mast Cells.
2007 Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.
2007 Nonredundant roles for Stat5a/b in directly regulating Foxp3.
2007 The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
2006 Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.
2006 Interferons limit inflammatory responses by induction of tristetraprolin.
2005 CD molecules 2005: human cell differentiation molecules.
2005 Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
2004 Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo.
2003 Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.
2003 JunB inhibits proliferation and transformation in B-lymphoid cells.
2002 Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.
2001 Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors.
2000 Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.
-
Gotthardt-Pötsch, Dagmar
2022 -
Kollmann, Karoline
2021 -
Grebien, Florian
2019 -
Hadzijusufovic, Emir
2016 -
Kenner, Lukas
2014 -
Klampfl, Thorsten
2014 -
Jensen-Jarolim, Erika
2012